Your Top 50 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
B.C. Cho, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jin Sun Lee, Soo Hoon Lee and 14 more
- Rank
- 38 of 3,639
- Percentile
- top 1.1%
- Where
- Annals of Oncology, 2023
- Citations
- 83
From the 2023 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.